Quarterly report pursuant to Section 13 or 15(d)

Recapitalization - Schedule of Net current assets (Details)

v3.23.3
Recapitalization - Schedule of Net current assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Sep. 16, 2022
Cash and cash equivalents $ 112,219 $ 167,467 $ 171,532  
Marketable securities $ 34,837    
Tyme Therapeutics, Inc.        
Cash and cash equivalents       $ 14,898
Marketable securities       52,220
Prepaid expenses       1,350
Total       $ 68,468